Development of Molecular Targeted Imaging for Prediction of Radiotherapy Effectiveness: Based on DNA Repair Mechanisms

2021 Fiscal Year Final Research Report

• Project/Area Number: 19H03600
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Single-year Grants
• Section: 一般
• Review Section: Basic Section 52040:Radiological sciences-related
• Research Institution: Hamamatsu University School of Medicine
• Principal Investigator: Magata Yasuhiro 浜松医科大学, 光尖端医学教育研究センター, 教授 (20209399)
• Co-Investigator(Kenkyū-buntansha): 中村 和正 浜松医科大学, 医学部, 教授 (20284507) ; 鈴木 千恵 浜松医科大学, 光尖端医学教育研究センター, 助教 (20637285)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 放射性医薬品 / PET / がん / 放射線治療 / コンパニオンイメージング / 治療予測

Outline of Final Research Achievements

Focusing on the molecular mechanisms related to DNA double-strand break repair, we developed a novel molecular targeted PET imaging probe, F-18-labeled F-PYK, in order to establish a clinically applicable “cancer radiotherapy prediction companion evaluation method”. F-18-labeled F-PYK is a novel mutated EGFR-TK imaging probe. F-18-labeled F-PYK accumulates in active mutations of L858R and ex19del, and as expected, these cell lines showed a high to moderate radiotherapeutic effect. On the other hand, cancer cells that did not accumulate F-18-labeled F-PYK showed moderate to low sensitivity to radiotherapy. These results indicate that the F-18-labeled F-PYK may be used to differentiate sensitivity to radiotherapy.

Free Research Field

核薬学

Academic Significance and Societal Importance of the Research Achievements

本研究が実用化されれば、DNA二重鎖切断を対象としたがん放射線治療や、シスプラチンなどのがん化学療法薬を実施する前に、対象とするがんに効果が高いかどうかを、がん生検などをすることなく、非侵襲的なインビボイメージングにより評価可能となる。これにより、治療効果の少ない治療法を試す必要が無く、患者にとって最も有効な治療法選択につながると期待される。